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ABSTRACT 
Cardiac arrest is shown to be a cause of a large 
number of deaths not only in Pakistan but 
around the globe. The prevalence of this dis-
ease demands identification of its etiology. The 
science of proteomics can be used to identify 
cardiac specific proteins. The subsequent over 
expression or under expression of these pro-
teins can be utilized as targets not only for 
therapeutical interventions but also for identi-
fying molecular signatures for Cardiac diseases. 
In context of a number of studies which  have 
shown that the specificity of serum biomarkers 
like troponin (cTnI and cTnT) are questionable 
as they may also appear in serum in pathologi-
cal conditions other than cardiac dysfunction, 
the search of a specific marker for cardiac arrest 
becomes imperative. In this study protein pro-
filing of cardiac arrest patients was performed 
after its quantification through Bradford assay. 
SDS-PAGE and 2 DE techniques were used as to 
characterize proteins. The samples of the pa-
tients prior to characterizing of proteins were 
subjected to lipid and cardiac enzymes profiling. 
The results of these investigations have shown 
an increase in almost all of these parameters by 
many folds from that of normal values. In addi-
tion to this the samples were found out to be 
positive for troponin T which strongly confirms 
the incidence of the cardiac arrest. The results 
of SDS-PAGE exhibited the induction of three 
proteins of 100 kDa, 97 kDa and of 66 kDa with 
100 kDa as the most highly expressed protein. In 
addition to that SDS-PAGE gels have shown the 
down regulation of 45 kDa protein, again indi-
cating the changes as a result of cardiac arrest. 
2DE gel patterns of cardiac arrest samples 
demonstrated higher number of protein spots as 
compare to control in the alkaline range, which 
might suggest their role in cardiac dysfunction. 
Therefore it can be concluded that this study 
may pave the grounds for identification of such 
proteins which can serve not only as potential 
therapeutical targets but also as candidate 
markers for accurate diagnosis of the disease. 
Keywords: Cardiac arrest; Troponins; Proteomics, 
SDS-PAGE; 2DE; Therapeutical Targets. 
1. INTRODUCTION 
Cardiovascular diseases(CVD) have been identified as 
being the single most significant cause of morbidity [1] 
and global mortality, accounting for almost 17 million 
deaths annually i.e. 30% of global mortality, moreover 
survival rates from cardiac arrest is less than 1% [2]. This 
situation is prevalent not only in the developing countries 
but in the western industrialized part of the world as well. 
The statistical analysis is in evidence to this, in United 
States of the 2 400 000 US deaths in 1999, 720 000 (30%) 
were directly attributed to cardiac diseases. Of this 
number, the US Centers for Disease Control and Preven-
tion estimated that 462 000, or 64% of the subtotal, were 
sudden cardiac deaths (SCDs) [3]. In the context of 
phenomenal advances in the physical and biological 
sciences, the limited number of viable therapeutic targets 
and effective cardiovascular therapies are a source of 
sheer surprise [4]. In addition to that, molecular causes 
underlying cardiac dysfunction in most heart diseases are 
unknown and expected to result from causal alterations in 
gene and protein expression [5]. Increasing body of evi-
dence suggest that examining changes in the protein ex-
pressions arising due to intrinsic and extrinsic perturba-
tions [4], offer insight into the understanding of cellular 
and molecular mechanisms that cannot be obtained from 
genomic analysis[6]. Proteins are considered to be the 
central executors of all life programs [7]. Up till now only 
150 proteins have been identified from human heart tissue 
using 2D-gel electrophoresis and sequencing [8]. There-
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fore in context of this situation, the emerging global 
trends of CVD demands identification of upstream and 
downstream effectors forming the basis of the disease 
which could also serve as targets for therapeutical inter-
vention. The myofilament proteins, including Troponin T 
are responsible for the contractile nature of the cardio-
myocytes. These proteins are highly regulated by a 
number of specific post translational modifications 
(PTMs), some of which have been discovered through 
proteomic studies [9]. These altered PTMs lead to heart 
failure and ischemia. Proteomic analysis facilitates in 
comprehending the pathophysiology of the diseases in 
non-biased manner and also provides oppourtunity for the 
development of a suite of candidate biomarkers for the 
diagnosis, staging and tracking of disease .Still, the 
number of useful cardiovascular biomarkers are limited 
[5]. Although, Troponin as proteins have proved to be 
ideal biomarkers because of being low molecular weight 
and due to complete specificity of the cardiac isoforms of 
TnT and TnI. These protein markers arise from damaged 
cardiomyocytes which release their cellular components 
into blood after necrosis [1]. 
Although the value of Troponins cannot be negated, yet 
there is a room for identification of more specific bio-
markers as, elevated serum troponins can be seen not only 
with acute cardiac injury but also with other non-cardiac 
disorders [10]. This risk factor creates possibility for 
pursuit of new biomarkers which decreases the risk of 
elevation of these in diseases secondary to myocardial 
infarction and may lead to wrong diagnosis of disease. 
The present study which employed the technology of 
proteomics is an effort in this regard, as with the advent of 
proteomics, it is possible to examine global alterations in 
the expression of diseased heart and hence has potential 
to provide insights into the molecular and cellular mecha- 
nisms of cardiac arrest. Ultimately, a better understanding 
of the role of these proteins should increase the likelihood 
of new effective therapies developed through rationale 
design [11]. 
2. MATERIALS AND METHODS 
2.1. Study Group 
Collection of serum samples was made from 50 appar-
ently healthy Pakistani male from University of Karachi. 
All of the subjects belonged to the same age group 
(35-40), were non smokers and were not on any type of 
medication. An equal number of samples were collected 
from patients with cardiac arrest pathology who pre-
sented themselves at Karachi University clinic. Prior to 
sampling, written consent was obtained from both groups 
of subjects and studies were carried out in accordance 
with human ethical approval from PCMD, University 
of Karachi. 
2.2. Sampling and Biochemical Analysis 
The samples taken were stored at-70oc until used for 
protein analysis. Prior to protein profiling serum from 
cardiac arrest patients was also evaluated for lipid profile 
and cardiac enzymes assay followed by Troponin T 
quantification. 
Assessment of different parameters of lipid profile was 
made, which included test for cholesterol Triglycerides, 
HDL and LDL and total lipids. HDL and LDL were 
measured using Cholestrol precipitant method.  
Cholesterol levels were estimated using kit-method 
specifically, CHOD-POD enzymatic colourimetric me- 
thod by spectrophotometer. The absorbance of the sample 
and the standards was read at 550 nm against the blank. 
TG levels were determined by using Bioscience kit spe-
cifically CPO-POD enzymatic colourimetric method. The 
absorbance of the samples and standards was read at 
505nm against the blank. 
HDL and LDL were measured using Cholestrol pre-
cipitant method.  
Precipitation of HDL and LDL cholesterol was made 
by using precipitating reagent, according to the kit 
method and the absorbance of the samples and standards 
was read at 500 nm against the blank. 
Cardiac enzyme profiling was carried out which in-
cluded tests for SGOT, CPK, LDH, and CK-MB. 
The SGOT levels in Cardiac arrest patients were esti-
mated spectrophotometrically by kit method at 340nm 
wavelength. The CPK levels in cardiac arrest patients 
were estimated spectrophotometrically by kit method at 
480 nm wavelength. The LDH levels in cardiac arrest 
patients were estimated spectrophotometrically by Breuer 
and Breuer kit method at 340,334 and 365 nm wave-
lengths. 
The CK-MB levels in cardiac arrest patients were es-
timated spectrophotometrically by Breuer and Breuer kit 
method at 340 nm and 334 nm wavelengths. 
2.3. Troponin T Quantification 
Troponin T quantification was made through Roche 
Cardiac T reader. 
2.4. Protein Quantification  
After biochemical analysis serum samples were subjected 
to protein quantification by using Bradford assay. 
2.5. Protein Characterization 
Separation of serum proteins was carried out using So-
dium Dodecyl Sulphate Polyacrylamide gel electropho-
resis (SDS-PAGE) of cardiac arrest samples. 
SDS-PAGE was performed in a Bio-Rad Mini-PROT- 
EAN III apparatus using Discontinuous gel system ac-
cording to Laemmli, 1970 protocol. The experiment was 
conducted in the electrode tank buffer. Tris/Glycine 
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(pH8.3) using 4% stacking gels and 10% separating gels. 
100g of protein was loaded on to the wells of the 
stacking gel. Glass plates were assembled with electrodes 
and electrode tank buffer was poured between the slabs. 
The comb was removed from stacking gel. 100g protein 
samples were loaded into each well along with 5 l of 
protein marker. Electrophoresis was carried out at con-
stant voltage of 90 volts. After completion of electro-
phoresis, the glass plates were taken out and gel was 
removed. The gel was left overnight in staining solution. 
The staining solution was discarded and destaining solu-
tion was added until a clear background was obtained and 
bands were visible. The gel was then photographed and 
analyzed through Quantity One software. 
Protein Profiling was carried out by Two Dimensional 
Gel Electrophoresis.The 2D electrophoresis was carried 
out by the modified procedure of O Farrell (1975). De-
naturing Acrylamide tube gels were used to separate 
proteins (isoelectric focusing, IEF) and then run on SDS- 
Polyacrylamide gel (10%).0.688g of urea was dissolved 
in 0.5 ml of double distilled water at 40oC in a water bath. 
0.16 ml monomer solution, 0.06 ml ampholytes and 0.025 
ml NP–40 were added. The solution was then de-
gassed.0.83l of TEMED and 5.83 l APS were added to 
solution and poured into the capillary tubes. Gels were 
allowed to polymerize for 1hr. Tubes and upper reservoir 
was filled with NaOH (2mM), while lower reservoir was 
filled was phosphoric acid. Gels were then pre-run at 
200V for 10 minutes, then at 300V for 15 minutes fol-
lowed by 400V for 15 minutes. After the pre-run, 100 g 
of protein samples was then loaded on the gel surface. 
9.0M urea (10l) was used to overlay the samples. The 
tubes and upper reservoir were filled again with NaOH 
(2mM). Gels were run at 750V for 5hrs. After isoelectric 
focusing, the gels were protruded from the tubes and 
equilibrated with SDB for 15 minutes. Gels were then 
loaded on the prepared SDS polyacrylamide gel (10% 
separating, 4% stacking). 0.5% Agarose was layered on 
the IEF gel and left to solidify for 15min. Electrophoresis 
was performed as for SDS-PAGE. The gel was then 
stained with Coomassie brilliant blue overnight. This was 
followed by destaining of the gels until a clear back-
ground was obtained and bands were visible. 
2.6. Silver Staining of Polyacrylamide Gels 
Silver staining protocol was used as described by Swan et 
al., (1995) for the visualization of proteins specifically 
low abundance protein. The gel was placed in fixative for 
10 min and then rinsed with double distilled water for 
another 10 min. The double distilled water was replaced 
with fixer/sensitizer for 15 min. Gel was rinsed first with 
ethanol (40%) and then with double distilled water for 20 
min each. For 1 min the gel was immersed in sensitizer, 
and then rinsed twice with double distilled water (1 
min/wash). Gel was then placed in staining solution for 
20 min and rinsed again in double distilled water for 1 
min. The bands were developed in the developer until the 
desire level of staining was obtained after which the de-
veloper was discarded and the gel was immersed in stop 
solution for 5 min. The stop solution was replaced with 
storage solution and the photograph of the gel was taken. 
Throughout the procedure the gel was agitated on an 
orbital shaker. 
2.7. Statistical Analysis 
Statistical analysis using student’s t test was carried out in 
order to establish the degree of significance for lipid profile 
and for assessment of cardiac enzymatic level for both the 
control and cardiac arrest samples. The p-value was found 
to be less than 0.001 with 95% confidence level which 




3.1. Protein Yield 
The protein yield of cardiac arrest patients and normal 
control were expressed as µg of protein per ml. As shown 
in Figure 1 the yield of serum protein samples was ±72. 
The protein yield of the diseased samples was found out 
to be much less than that of the controls which is in direct 
relation to the cardiac arrest pathology. 
3.2. Lipid Profile 
The lipid profile test was performed on samples of car-
diac arrest and on its respective control before protein 
profiling was carried out (see Table 1). 
Comparison between normal serum and control of 
different plasma lipid parameters was performed in order 
to assess the degree of severity of the pathology as shown 
in Figure 2. It was found out that there is a 1.44796 fold 
increase in cholesterol levels followed by a 0.775 fold 
decrease in TG levels, 1.415 decrease in HDL levels, 
1.266 fold increase in LDL levels and 1.322fold increase 
in total lipids when comparison was made between car-
diac arrest sample and its respective control. 
 
Figure 1. Quantification of proteins in cardiac ar-
rest sample by ELISA using Bradford Assay. 
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Table 1. Comparison and contrast between control and cardiac 
arrest sample of different plasma lipid parameters. 
Parameters Normal serum (mg/dl) 
Cardiac arrest 
sample (mg/dl) 
Cholesterol 200±14.61 288.9592±14.59 
Triglycerides(TG) 274±14.14 212.3878±16.86 
HDL 59±14.152 41.69388±4.77 
LDL 154±14.16 195.0612±16.22 
Total. lipids 624±14.15 825±14.710 
HDL: High density lipoproteins 
































Figure 2. (a) Standard error bars for different parameters 
of lipid profiling of controls. (n=50, p>0.001). (b) Stan-
dard error bars for different parameters of lipid profiling 
of cardiac arrest sample (n= 50, p>0.001). 
3.3. Cardiac Enzyme Test 
Tests were performed on serum samples of cardiac arrest 
patients and their respective control for assessment of 
cardiac enzyme levels. When comparative studies were 
made it was found out that SGOT level demonstrated an 
increase by 2.988 fold, CPK by 1.246 fold LDH by 
1.31935 fold and CK-MB by 2.34fold between serum of 
diseased patients and control (see Table 2). 
3.4. Troponins T Test 
The cardiac arrest samples used were found out to be 
troponin T positive. The tests for troponins are carried out 
in situations when there is a many fold increase in HDL, 
LDL and cholesterol levels of the patient. The troponin T 
values of all the healthy subjects were assumed to be 































Figure 3. (a) Standard error bars for cardiac enzymatic 
levels of control. (n=50, p>0.001). (b) Standard error bars 
for cardiac enzymatic levels of cardiac arrest sample. 
(n=50, p>0.001). 
 
Table 2. Comparisons and contrast of different cardiac enzymes 
in normal serum and cardiac arrest sample. 
Cardiac enzymes Normal serum (µ/l) Cardiac arrest sample
SGOT 24.5±1.414 73.2449±15.78 
CPK 173.35±7.77 216.1633±14.08 
LDH 324±14.142 427.4694 ±22.87 
CK-MB 22.4±1.414 52.4898±13.73 
SGOT: Serum glutamic oxaloacetic transaminase 
CPK: Creatine phosphokinase 
LDH: Lactate dehydrogenase 
CK-MB: Creatinine Kinase 
 
of patients were found out to be within (0.8-1.04±0.1413) 
which is in absolute concordance with the established 
ranges for the determination of myocardial damage. (0.1- 
2.0 ng/ml). 
3.5. Protein Components Analyzed Using 
SDS-PAGE (10%) 
Serum protein (100g) of control and cardiac arrest pa-
tients (n=50 for each group) were subjected to SDS Page 
(10%). The proteins were visualized by Coomassie bril-
liant blue. 
As shown in Figure 4 the electrophoretic patterns of 
the components of control (normal serum) and of cardiac 
arrest sample demonstrated approximately 16 and 9 
bands respectively in the silver stained gel. The molecular 
weight of the protein components ranged from 200- 
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25kDa. The silver stained electrophoretic patterns were 
used for the molecular weight determination and semi- 
quantitative analysis was made using Quantity one soft-
ware. Protein components (P1, P7, P11, P14, and P16) 
with molecular weights (200kDa, 100kDa, 97kDa, 66kDa, 
45kDa and 25 kDa) respectively were found to be both 
common in control and cardiac arrest sample as shown in 
Table 3. The difference in expression of protein compo-
nents between control and cardiac arrest patient samples 
was obtained through R.Q values (see Table 4 The 
135kDa (P4), 116kDa (P6), 87kDa (P9) protein compo-
nents were present in the cardiac arrest sample but were 
absent in normal control. The results showed that the 
45kDa (P14) protein present in control was under ex-
pressed or down regulated in cardiac arrest sample, where 
as the 100kDa (P7), 97kDa (P8) and 66kDa (P11) were 
over expressed in cardiac arrest samples (see Table 5). 
There was a 5.6 fold up regulation of 100kDa protein, 
4.5 fold up regulation of 97 kDa protein, while 2.13 fold 
up regulation of 66 kDa protein, and in contrast there was 
a 0.75 fold, down regulation of 45kDa protein in the 
serum of cardiac arrest patients. 100kDa molecular wei- 
ght protein was the most highly expressed followed by 
97kDa and 45kDa. Differential expression of above 
mentioned proteins in cardiac arrest patients illustrate 
their possible role in the pathogenesis of cardiac arrest. 
100kDa, 97kDa and 45kDa proteins can be identified as 
potential markers of cardiac arrest .Up regulation of these 
proteins are involved in the pathogenesis of this disease. 
Low level of 45 kDa protein depicts that the high level of 
this protein should be maintained to avoid the patho-
genesis. 
3.6. Protein Components Resolved Using 
Isoelectric Focusing (IEF) 
2 DE performed on cardiac arrest sample had shown large 
number of proteins in acidic range of pI range of 4.75-7.1 
(see Figure 6), however those proteins which were ex-
clusively expressed in cardiac arrest sample were alkaline 
in nature with pI range 7.6-10. The 2DE gel patterns of 
control showed large number of proteins towards  acidic 
side with in the pI range of 4.3-6.4(see Figure 5).While 
there are only 8 protein spots present in control as well as 
in the diseased samples and were in the pI range 4.6 to 8.2. 
This is an important observation suggesting a possible 
role of alkaline proteins in the progression of cardiac 
arrest and can be confirmed in future after further char-
acterization. 
These findings suggest the potential role of these pro-
teins in disease progression and pathology. The altered 
expression of several proteins observed in the present 
study strengthened the hypothesis of the involvement of 
these proteins in disease etiology. The proteins identified 
here could be used in future as diagnostic and therapeutic 
biomarker. 
 
Figure 4. SDS-PAGE analysis of cardiac arrest sample, with normal serum and marker. 
Openly accessible at  
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Figure 5. 2D gel electrophoresis serum proteins from controls resolved through IEF and visualized by silver staining. The 
spots show differentially expressed proteins. Protein marker used was with in the range of Mr 66-24kDa. 
 
Figure 6. 2DE electrophoretic pattern of cardiac arrest proteins resolved through IEF and visualized by silver staining. The spots 
show differentially expressed proteins Protein marker use was with in the range of Mr 200-29 kDa.
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Table 3. Difference in expression of protein components be-
tween control and cardiac arrest patient samples as obtained 












P1 200 3.8 3.7 
P2 165 2.3 - 
P3 155 3.3 - 
P4 135 - 4.8 
P5 120 2.6 - 
P6 116 - 5.1 
P7 100 2.4 13.6 
P8 97 2.3 10.3 
P9 87 - 4.4 
P10 76 4.6 - 
P11 66 4.5 9.6 
P12 62 4.9 - 
P13 52 2.7 - 
P14 45 5.4 4.1 
P15 35 3.0 - 
P16 25 0.9 0.2 
 
Table 4. Protein components differentially expressed as in car- 





weight(kDa) Control Cardiac arrest sample
P1 200 + + 
P2 189 - + 
P3 165 + - 
P4 155 + - 
P5 120 + - 
P6 116 - + 
P7 100 + + 
P8 97 + + 
P9 87 - + 
P10 76 + - 
P11 66 + + 
P12 62 + - 
P13 52 + - 
P14 45 + + 
P15 35 + - 
P16 25 + + 
 
Table 5. Protein components of patient in control and cardiac 







P7 100 normal up regulate 
P8 97 normal up regulate 
P11 66 normal up regulate 
P14 45 normal down regulate 
4. DISCUSSION 
Heart diseases resulting in heart failure are a leading 
cause of morbidity and mortality in developing countries 
[1]. In context of this situation, the importance of a spe-
cific biomarker which precisely marks the prognosis of 
the disease like cardiac arrest, increases by many folds. In 
terms of availability and ease of measurement , a protein  
that is very abundant in the target cell, has a means of 
reaching blood and ideally a specific form reflective only 
of the target cell in the tissue can serve out to be a good 
candidate marker. We focused on heart muscle contractile 
proteins as their levels in blood reflect the amount of 
damage to the heart due to the necrosis of cardiomyocytes 
[12]. The quest for a specific biomarker for ischemic 
injury and heart failure began in 1950 and in 1990’s 
trponins, specifically cardiac TnT and TnI became ideal 
because of their low molecular weight, the apparent 
specificity of the cardiac isoforms of TnT and TnI for the 
myocardium and in addition to this, the ease with which 
they can be detected in serum by chemical laboratory 
analysis, 4-6 hours of an acute event and may remain 
elevated for 7-10 days after the event [10]. However, 
elevated serum troponins can be seen not only with acute 
cardiac injury but also with other non-cardiac disorders 
including pulmonary embolus, sepsis and renal failures, a 
number of studies [13-15], have confirmed that cTnI 
along with cTnT were found to be elevated in renal failure 
cases. This finding supported our search of a more spe-
cific protein as biomarker for cardiac arrest. 
Nevertheless, the presence of troponins in the serum 
are detected only after the occurrence of cardiac injury.i.e 
when the ideal period for thereuptical intervention has 
passed by a large extent.Consequently, the present study 
was an effort in this regard. In this study, the serum 
sample of only those cardiac arrest patients were included, 
which were found out to be positive for troponins cTnT 
and cTnI so in the presence of these established bio-
markers, some new proteins could be identified which 
could serve the purpose of new diagnostic or prognostic 
biomarkers. Apart, from that another move was made 
towards the discovery of such proteins which could serve 
as potential drug targets for the development of new 
thereuptical approaches for combating heart diseases. As 
a result of which in this study, protein components from 
cardiac arrest sample and their respective controls were 
differentially expressed on SDS-PAGE gel pattern and 
2DE.Most of the diseases cause induction or suppression 
of some proteins associated with them. Differentially 
expressed three proteins P7(100kDa), P8(97kDa),and 
P11(66kDa) on SDS-PAGE were found out to be over 
expressed in the cardiac arrest sample ,suggesting their 
role in progression of disease while it can be hypothe-
sized that normal expression of the  P14(45kDa) which 
was found out to be  down regulated in this study can be 
conducive in rectification of the disease. From 2DE gel 
patterns of the cardiac arrest samples it can be concluded 
that that there is a role of alkaline proteins in the etiology 
of the disease. The overall study concludes that the above 
mentioned three proteins with 100kDa protein being the  
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Table 6. Difference in expression of protein components be-
tween control and cardiac arrest patient samples as obtained 
through R.f values using graphical methods. The protein com-
ponents were obtained through 2D gel electrophoresis. 
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